175 related articles for article (PubMed ID: 32281272)
21. Induction chemoimmunotherapy may improve outcomes of chemoradiotherapy in patients with unresectable stage III NSCLC.
Guan S; Zhang S; Ren K; Li X; Li X; Zhao L
Front Immunol; 2023; 14():1289207. PubMed ID: 38090575
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
Yamada T; Goto Y; Tanaka H; Kimura H; Minato K; Gyotoku H; Honda T; Watanabe S; Morimoto K; Kiyomi F; Uchino J; Takayama K
Eur J Cancer; 2023 Dec; 195():113373. PubMed ID: 37890349
[TBL] [Abstract][Full Text] [Related]
23. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A; Taus Á; Álvarez Álvarez R; Bernabé-Caro R; Chara L; López-Brea M; Vilà L; Sala González MÁ; Del Barrio Díaz Aldagalán A; Esteban Herrera B; López Castro R; Álvarez Cabellos R; Doménech M; Falagan S; Moreno Vega A; Aguado C; Barba A; Delgado Ureña MT; Isla D; Bellido Hernández L; Fírvida Pérez JL; Juan-Vidal Ó; Massutí B; Mielgo-Rubio X; Ortega AL; Catot S; Dómine M; Escoín-Pérez C; García Navalón F; Gil-Bazo I; Muñoz S; Rodríguez-Abreu D; Villatoro Roldán RM; Alonso-Jáudenes Curbera G; León-Mateos L; Padilla A; Paredes Lario A; Sánchez-Torres JM; Garrido P;
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38512450
[TBL] [Abstract][Full Text] [Related]
24. Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting.
Waterhouse D; Yong C; Frankart A; Brannman L; Mulrooney T; Robert N; Aguilar KM; Ndukum J; Cotarla I
Future Oncol; 2023 Sep; 19(28):1905-1916. PubMed ID: 37497677
[TBL] [Abstract][Full Text] [Related]
25. Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K; Mizugaki H; Yokoo K; Kobayashi M; Kawashima Y; Kimura N; Yokouchi H; Kikuchi H; Sumi T; Kawai Y; Kobashi K; Morita R; Ito K; Kitamura Y; Minemura H; Nakamura K; Aso M; Honjo O; Tanaka H; Takashina T; Tsurumi K; Sugisaka J; Tsukita Y; Konno S; Oizumi S
Cancer Sci; 2024 Apr; 115(4):1273-1282. PubMed ID: 38287788
[TBL] [Abstract][Full Text] [Related]
26. Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
Käsmann L; Eze C; Taugner J; Nieto A; Hofstetter K; Kröninger S; Guggenberger J; Kenndoff S; Flörsch B; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7393-7403. PubMed ID: 36939927
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Jinnnouchi M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Cancer Immunol Immunother; 2021 Jun; 70(6):1745-1753. PubMed ID: 33389013
[TBL] [Abstract][Full Text] [Related]
28. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH; Kim SY; Aredo JV; Feng J; Shepherd F; Xu C; Kaldas D; Gray JE; Dilling TJ; Neal JW; Wakelee HA; Liu Y; Lin SH; Abuali T; Amini A; Nie Y; Patil T; Lobachov A; Bar J; Fitzgerald B; Fujiwara Y; Marron TU; Thummalapalli R; Yu H; Owen DH; Sharp J; Farid S; Rocha P; Arriola E; D'Aiello A; Cheng H; Whitaker R; Parikh K; Ashara Y; Chen L; Sankar K; Harris JP; Nagasaka M; Ayanambakkam A; Velazquez AI; Ragavan M; Lin JJ; Piotrowska Z; Wilgucki M; Reuss J; Luders H; Grohe C; Baena Espinar J; Feiner E; Punekar SR; Gupta S; Leal T; Kwiatkowski DJ; Mak RH; Adib E; Naqash AR; Goldberg SB
J Thorac Oncol; 2024 Jan; ():. PubMed ID: 38278303
[TBL] [Abstract][Full Text] [Related]
29. Metabolic patterns on [
Holzgreve A; Taugner J; Käsmann L; Müller P; Tufman A; Reinmuth N; Li M; Winkelmann M; Unterrainer LM; Nieto AE; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Unterrainer M; Manapov F
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2466-2476. PubMed ID: 36951991
[TBL] [Abstract][Full Text] [Related]
30. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
Garassino MC; Mazieres J; Reck M; Chouaid C; Bischoff H; Reinmuth N; Cove-Smith L; Mansy T; Cortinovis D; Migliorino MR; Delmonte A; Sánchez JG; Chara Velarde LE; Bernabe R; Paz-Ares L; Perez ID; Trunova N; Foroutanpour K; Faivre-Finn C
J Thorac Oncol; 2022 Dec; 17(12):1415-1427. PubMed ID: 35961520
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer.
Bryant AK; Sankar K; Strohbehn GW; Zhao L; Elliott D; Qin A; Yentz S; Ramnath N; Green MD
Lung Cancer; 2022 Jan; 163():35-41. PubMed ID: 34896803
[TBL] [Abstract][Full Text] [Related]
32. First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET.
Pouw JEE; Hashemi SMS; Huisman MC; Wijngaarden JE; Slebe M; Oprea-Lager DE; Zwezerijnen GJC; Vugts D; Ulas EB; de Gruijl TD; Radonic T; Senan S; Menke-van der Houven van Oordt CW; Bahce I
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302416
[TBL] [Abstract][Full Text] [Related]
33. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer.
Xu T; Wu L; Gandhi S; Jing W; Nguyen QN; Chen A; Chang JY; Nurieva R; Sheshadri A; Altan M; Lee PP; Lin SH; Liao Z
Radiother Oncol; 2022 Nov; 176():149-156. PubMed ID: 36209942
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
McCall NS; Janopaul-Naylor JR; McGinnis HS; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal TA; Ramalingam SS; Bradley JD; Higgins KA
Cancer; 2023 Dec; 129(23):3713-3723. PubMed ID: 37354070
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis.
Zhao L; Zhao Z; Yan X; Wu F; Sun N; Guo R; Yu S; Hu X; Feng J
Int J Clin Pract; 2024; 2024():8585035. PubMed ID: 38375028
[TBL] [Abstract][Full Text] [Related]
36. Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.
Damhuis RAM; Dickhoff C; Bahce I; Senan S
Lung Cancer; 2024 Apr; 190():107532. PubMed ID: 38461767
[TBL] [Abstract][Full Text] [Related]
37. Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer.
Edwards DM; Sankar K; Alseri A; Jiang R; Schipper M; Miller S; Dess K; Strohbehn GW; Elliott DA; Moghanaki D; Ramnath N; Green MD; Bryant AK
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):963-970. PubMed ID: 37793573
[TBL] [Abstract][Full Text] [Related]
38. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
Haratani K; Nakamura A; Mamesaya N; Sawa K; Shiraishi Y; Saito R; Tanizaki J; Tamura Y; Hata A; Tsuruno K; Sakamoto T; Teraoka S; Oki M; Watanabe H; Tokito T; Nagata K; Masuda T; Nakamura Y; Sakai K; Chiba Y; Ito A; Nishio K; Yamamoto N; Nakagawa K; Hayashi H
Br J Cancer; 2024 May; 130(11):1783-1794. PubMed ID: 38519705
[TBL] [Abstract][Full Text] [Related]
39. Metformin use and lung cancer survival: a population-based study in Norway.
Brancher S; Støer NC; Weiderpass E; Damhuis RAM; Johannesen TB; Botteri E; Strand TE
Br J Cancer; 2021 Mar; 124(5):1018-1025. PubMed ID: 33262518
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab.
Gavrilov S; Zhudenkov K; Helmlinger G; Dunyak J; Peskov K; Aksenov S
CPT Pharmacometrics Syst Pharmacol; 2021 Jan; 10(1):67-74. PubMed ID: 33319498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]